Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. ( TRML ) : Here's What You Should Know
The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Tourmaline Bio Reports Loss as R&D Rises
Tourmaline Bio ( NASDAQ:TRML ) , a clinical-stage biotechnology company focusing on treatments for inflammatory diseases, published its earnings for the second quarter on August 13, 2025. The most notable headline was the positive clinical milestone from its Phase 2 TRANQUILITY trial for its lead ...
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Amer Sports ( NYSE:AS ) , Ekso Bionics Holdings ( NASDAQ:EKSO )
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 150 points on Tuesday. The Dow traded down 0.37% to 42,632.71 while the NASDAQ fell 0.43% to 19,132.73. The S&P 500 also fell, dropping, 0.42% to 5,938.36. Utilities shares rose by 0.3% on Tuesday.
Trip.com Posts Weak Earnings, Joins Vipshop, Viking Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Asana ( NYSE:ASAN ) , Elong Power Holding ( NASDAQ:ELPW )
U.S. stock futures were mixed this morning, with the Nasdaq futures falling around 0.3% on Tuesday. Shares of Trip.com Group Limited TCOM fell sharply in today's pre-market trading following weaker-than-expected quarterly earnings.
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
NEW YORK, May 19, 2025 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) ( NASDAQ: TRML ) , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a ...
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
- Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 -
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
- Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the second quarter of 2025 - - Cardiovascular Scientific Advisory Board strengthened with recent ...
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - ImmunityBio ( NASDAQ:IBRX ) , Aduro Clean Technologies ( NASDAQ:ADUR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Andrew Fein initiated coverage on ImmunityBio, Inc.
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
NEW YORK, March 03, 2025 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) ( NASDAQ: TRML ) , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced ...
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025 - Tourmaline Bio ( NASDAQ:TRML )
NEW YORK, March 03, 2025 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) TRML, a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep ...
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Beta Bionics ( NASDAQ:BBNX ) , Compass Therapeutics ( NASDAQ:CMPX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Barclays analyst Benjamin Budish initiated coverage on Blue Owl Capital Inc.
Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference - Tourmaline Bio ( NASDAQ:TRML )
NEW YORK, Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) TRML, a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep ...
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
Paul M. Ridker, MD, MPH, has joined Tourmaline's Cardiovascular Scientific Advisory Board (CV SAB).
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
- Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of 2025 - - Company nominates abdominal aortic aneurysm as second cardiovascular indication for pacibekitug, expanding development for inflammation-driven ...
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
Tourmaline Bio to Host Investor Day on Tuesday, December ...
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024 - Tourmaline Bio ( NASDAQ:TRML )
NEW YORK, Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) TRML, a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will ...
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress - Tourmaline Bio ( NASDAQ:TRML )
NEW YORK, Oct. 11, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) TRML, a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that it ...
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
NEW YORK, Oct. 11, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) ( NASDAQ: TRML ) , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced ...
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board - Tourmaline Bio ( NASDAQ:TRML )
- Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases - - Cardiovascular Scientific Advisory Board expected to provide strategic guidance as Tourmaline advances pacibekitug towards potential Phase 3 clinical trial readiness in 2025 for the ...
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
- Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases - - Cardiovascular Scientific Advisory Board expected to provide strategic guidance as Tourmaline advances pacibekitug towards potential Phase 3 clinical trial readiness in 2025 for the ...
Tourmaline Bio to Present at Upcoming Investor Conferences
NEW YORK, Sept. 03, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) ( NASDAQ: TRML ) , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced ...
Tourmaline Bio to Present at Upcoming Investor Conferences - Tourmaline Bio ( NASDAQ:TRML )
NEW YORK, Sept. 03, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) TRML, a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep ...
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- First patient dosed in May 2024 in Phase 2 TRANQUILITY trial evaluating pacibekitug ( TOUR006 ) in patients with high cardiovascular risk - - On track to initiate a pivotal Phase 3 trial evaluating pacibekitug delivered subcutaneously every 8 weeks as first-line treatment for Thyroid Eye ...
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology ( ASPC ) Congress 2024
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress ...
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology ( ASPC ) Congress 2024 - Tourmaline Bio ( NASDAQ:TRML )
Phase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein ( hs-CRP ) -lowering effect, safety, tolerability, and pharmacokinetics ( PK ) of quarterly and monthly subcutaneous administration of TOUR006 in patients with chronic kidney disease and elevated hs-CRP -
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
NEW YORK, June 27, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) ( NASDAQ: TRML ) , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced ...
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference - Tourmaline Bio ( NASDAQ:TRML )
NEW YORK, May 23, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) TRML, a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep ...
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
Sandeep Kulkarni, CEO of Tourmaline Bio, is expected to participate in the Jefferies Global Healthcare Conference in New York on June ...
Dow Jumps 200 Points; US Weekly Jobless Claims Fall - Intelligent Group ( NASDAQ:INTJ ) , Asset Entities ( NASDAQ:ASST )
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.52% to 39,718.37 while the NASDAQ rose 0.84% to 16,506.28. The S&P 500 also rose, gaining, 0.53% to 5,252.23.
Five Below Posts Q4 Results, Joins LexinFintech And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Five Below ( NASDAQ:FIVE ) , LexinFintech Holdings ( NASDAQ:LX )
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday. Shares of Five Below, Inc. FIVE fell sharply in today's pre-market trading after the company reported fourth-quarter financial results.
Here's Why Momentum in Tourmaline Bio, Inc. ( TRML ) Should Keep going
Tourmaline Bio, Inc. (TRML) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Here's What Could Help Tourmaline Bio, Inc. ( TRML ) Maintain Its Recent Price Strength
Tourmaline Bio, Inc. (TRML) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Tourmaline Bio to Present at Upcoming Investor Conferences
NEW YORK, Feb. 27, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) ( NASDAQ: TRML ) , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced ...
What Makes Tourmaline Bio, Inc. ( TRML ) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Tourmaline Bio, Inc. (TRML) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies
Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech ... PR ...
Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference - Tourmaline Bio ( NASDAQ:TRML )
NEW YORK, Feb. 01, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( Tourmaline ) TRML, a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep ...
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares - Tourmaline Bio ( NASDAQ:TRML )
NEW YORK, Jan. 29, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( "Tourmaline" ) TRML, a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the closing ...
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
NEW YORK, Jan. 25, 2024 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( "Tourmaline" ) ( Nasdaq: TRML ) , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today ...
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease ( TED ) and Atherosclerotic Cardiovascular Disease ( ASCVD ) - Tourmaline Bio ( NASDAQ:TRML )
Tourmaline plans to accelerate the initiation of a pivotal Phase 3 trial in 2024 evaluating subcutaneous TOUR006 every 8 weeks as first-line treatment for TED, with topline data expected in 2026
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday - Arrowhead Pharma ( NASDAQ:ARWR ) , Anavex Life Sciences ( NASDAQ:AVXL )
U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. TDCX rose sharply during Wednesday's session after it disclosed receiving a preliminary non-binding acquisition offer.
Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday - Allogene Therapeutics ( NASDAQ:ALLO ) , Altair Engineering ( NASDAQ:ALTR )
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. KRTX rose sharply during Friday's session following acquisition news.
Tourmaline Bio added to the NASDAQ Biotechnology Index
NEW YORK, Dec. 15, 2023 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( "Tourmaline" ) ( Nasdaq: TRML ) , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today ...
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
NEW YORK, Dec. 14, 2023 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( "Tourmaline" ) ( NASDAQ: TRML ) , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced ...
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board - Tourmaline Bio ( NASDAQ:TRML )
NEW YORK, Dec. 14, 2023 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( "Tourmaline" ) TRML, a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that Clay ...
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday - Arista Networks ( NYSE:ANET ) , Ardelyx ( NASDAQ:ARDX )
U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today's session. Verve Therapeutics, Inc. VERV gained 27% to $11.95.
Tourmaline Bio Director Trades Company's Stock - Tourmaline Bio ( NASDAQ:TRML )
Parvinder Thiara, Director at Tourmaline Bio TRML, reported a large insider buy on October 26, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Thiara purchased 7,000 shares of Tourmaline Bio.
